Stephen Chia

23.6k total citations · 6 hit papers
234 papers, 11.5k citations indexed

About

Stephen Chia is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stephen Chia has authored 234 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Oncology, 123 papers in Cancer Research and 109 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stephen Chia's work include Breast Cancer Treatment Studies (95 papers), Advanced Breast Cancer Therapies (94 papers) and HER2/EGFR in Cancer Research (83 papers). Stephen Chia is often cited by papers focused on Breast Cancer Treatment Studies (95 papers), Advanced Breast Cancer Therapies (94 papers) and HER2/EGFR in Cancer Research (83 papers). Stephen Chia collaborates with scholars based in Canada, United States and Spain. Stephen Chia's co-authors include Torsten O. Nielsen, Maggie C.U. Cheang, Samuel Leung, Charles M. Perou, Karen A. Gelmon, David Voduc, Chris Bajdik, Caroline Speers, Dongxia Gao and Ivo A. Olivotto and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Stephen Chia

225 papers receiving 11.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. profile →
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

2008 945 citations Maggie C.U. Cheang, Samuel Leung et al. Clinical Cancer Research profile →
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

2013 774 citations Stephen Chia et al. Annals of Oncology profile →
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma

2001 364 citations Stephen Chia et al. Journal of Clinical Oncology profile →
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

2021 223 citations Hope S. Rugo, Patrick Neven et al. profile →
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021 161 citations Dennis J. Slamon, Patrick Neven et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Stephen Chia

Since Specialization

Citations

This map shows the geographic impact of Stephen Chia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Chia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Chia more than expected).

Fields of papers citing papers by Stephen Chia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Chia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Chia. The network helps show where Stephen Chia may publish in the future.

Co-authorship network of co-authors of Stephen Chia

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Chia. A scholar is included among the top collaborators of Stephen Chia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Chia. Stephen Chia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial 2025 ·Clinical Cancer Research ·Peter A. Fasching, Dennis J. Slamon, Zbigniew Nowecki, (unknown), Daniil Stroyakovskiy, DA Yardley, Chiun‐Sheng Huang, Arlene Chan, Stephen Chia, Miguel Martín, Hope S. Rugo, Sherene Loi, Sara A. Hurvitz, Michael Untch, Karen Afenjar, Rodrigo Fresco, Andriy Danyliv, (unknown), (unknown), Gabriel N. Hortobágyi	2
2	Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial 2024 ·Clinical Cancer Research ·Eleftherios P. Mamounas, Hanna Bandos, Priya Rastogi, (unknown), Kai Treuner, Peter C. Lucas, Charles E. Geyer, Louis Fehrenbacher, Stephen Chia, Adam Brufsky, Janice M. Walshe, Gamini S. Soori, Shaker R. Dakhil, Soonmyung Paik, Sandra M. Swain, Dennis C. Sgroi, Catherine A. Schnabel, Norman Wolmark	7
3	Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors 2024 ·Cancer Research Communications ·(unknown), (unknown), Emma Titmuss, Robert J. Vanner, David F. Schaeffer, Aly Karsan, Howard J. Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, Stephen Chia, Hagen F. Kennecke, Derek J. Jonker, Eric X. Chen, Daniel J. Renouf, Chris J. O’Callaghan, Jonathan M. Loree	2
4	Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response 2024 ·Journal of Clinical Oncology ·Carmine Valenza, Dario Trapani, Sibylle Loibl, Stephen Chia, Harold J. Burstein, Giuseppe Curigliano	2
5	Abstract PO3-15-04: Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive, HER2-negative Breast Cancers 2024 ·Cancer Research ·Lidiya Luzhna, Stephen Chia, (unknown), Nathalie LeVasseur	0
6	Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer 2024 ·Current Oncology ·Jeffrey Cao, (unknown), (unknown), Jean-François Boileau, Karen A. Gelmon, Muriel Brackstone, Christine Brezden‐Masley, (unknown), (unknown), Sandeep Sehdev, Stephanie M. Wong, Nathaniel Bouganim, David W. Cescon, Stephen Chia, Ian S. Dayes, Anil A. Joy, Jan‐Willem Henning	2
7	Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). 2024 ·Journal of Clinical Oncology ·Kevin Kalinsky, William E. Barlow, Harsh B. Pathak, Julie R. Gralow, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Stephen Chia, Priya Rastogi, Anne F. Schott, Steven Shak, (unknown), Gabriel N. Hortobágyi, Funda Meric‐Bernstam, Priyanka Sharma, Lajos Pusztai, Alastair M. Thompson, Andrew K. Godwin	5
8	196P Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2 2023 ·ESMO Open ·Joyce O’Shaughnessy, (unknown), Stephen Chia, Claudine Isaacs, Michelino De Laurentiis, Sherko Küemmel, Komal Jhaveri, Wolfgang Janni, Hope S. Rugo, Agnes Lteif, (unknown), Howard Hu, Patrick Neven	0
9	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant 2023 ·Breast Cancer Research ·Patrick Neven, PA Fasching, Stephen Chia, Guy Jérusalem, Michelino De Laurentiis, Seock‐Ah Im, Katarína Petráková, Giulia Bianchi, (unknown), Arnd Nusch, Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, Juan Pablo Zarate, (unknown), A. Chakravartty, (unknown), Dennis J. Slamon	33
10	Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective 2023 ·Current Oncology ·Jan‐Willem Henning, Christine Brezden‐Masley, Karen A. Gelmon, Stephen Chia, Shane Shapera, Micheal McInnis, Daniel Rayson, Jamil Asselah	17
11	Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer 2021 ·International Journal of Radiation OncologyBiologyPhysics ·Daegan Sit, Nafisha Lalani, Elisa Chan, Eric Tran, (unknown), Lovedeep Gondara, Stephen Chia, Karen A. Gelmon, Caroline Lohrisch, Alan Nichol	2
12	Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study 2021 ·Clinical Breast Cancer ·Nathalie LeVasseur, (unknown), David Fenton, Simon W. Baxter, Angela Chan, (unknown), Xiaolan Feng, Caroline Lohrisch, Karen A. Gelmon, Tamara Shenkier, Stephen Chia	9
13	ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials 2020 ·Clinical Cancer Research ·Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac García-Murillas, Aman U. Budzar, J.F.R. Robertson, William J. Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen Johnston, Stephen Chia	100
14	A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen 2012 ·Clinical Cancer Research ·Stephen Chia, Vivien Bramwell, Dongsheng Tu, Lois E. Shepherd, Shan Jiang, Tammi L. Vickery, Elaine R. Mardis, Samuel Leung, Karen Ung, Kathleen I. Pritchard, Joel S. Parker, Philip S. Bernard, Charles M. Perou, Matthew J. Ellis, Torsten O. Nielsen	220
15	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial 2012 ·Clinical Cancer Research ·Maggie C.U. Cheang, K. David Voduc, Dongsheng Tu, Shan Jiang, Samuel Leung, Stephen Chia, Lois E. Shepherd, Mark N. Levine, Kathleen I. Pritchard, Sherri R. Davies, Inge J. Stijleman, Carole Davis, Mark Ebbert, Joel S. Parker, Matthew J. Ellis, Philip S. Bernard, Charles M. Perou, Torsten O. Nielsen	105
16	Year in review for local/triple negative/cytotoxic therapy (ASCO 2011) (The 49th annual meeting of Japanese Society of Clinical Oncology educational book) -- (JSCO University: Breast cancer) 2011 ·Stephen Chia	1
17	What Is the Difference Between Triple-Negative and Basal Breast Cancers? 2010 ·The Cancer Journal ·Melanie Seal, Stephen Chia	35
18	Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality 2010 ·Current Oncology ·(unknown), (unknown), Sayeh Lavasani, John R. Mackey, Kathleen I. Pritchard, Mark Clemons, Susan Dent, Jean Latreille, Julie Lemieux, Louise Provencher, (unknown), (unknown), Stephen Chia, Bo Wang, Daniel Rayson	23
19	Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors 2009 ·Clinical Cancer Research ·Gerald Batist, Karen A. Gelmon, Kim N., Wilson H. Miller, Stephen Chia, Lawrence D. Mayer, Christine E. Swenson, Andrew S. Janoff, Arthur C. Louie	166
20	Anthracycline–trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies 2008 ·Annals of Oncology ·Daniel Rayson, D. J. Richel, Stephen Chia, Christian Jackisch, S. van der Vegt, Thomas Suter	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact